For users without scalp irritation, most users report nothing perceptible during application or in the hours afterward. The molecule is not psychoactive, does not change libido at design-intent doses, and has no acute physiological effects.

Effects on hair appear over months:

• Weeks 1-4: Often described as a "shed" phase (similar to the early-minoxidil shed) — synchronized exit of miniaturized follicles into telogen as the AR signal lifts. Distressing for new users; usually transient.
• Months 2-3: Stabilization of shedding; sometimes slight density improvement appreciable on photographs but not in the mirror.
• Months 4-6: Recovery of vellus → terminal transitions; visible density improvement at temples and vertex in responders.
• Months 6-12: Full effect in responders; non-responders are usually clear by this point and discontinue.
• Discontinuation: Effect reverses over ~3-6 months as DHT regains AR access. There is no "lock-in" of regrown follicles — RU58841 is a chronic-use molecule, like all hair-loss drugs except hair transplantation.

Adverse subjective effects (when they occur):

• Scalp itch, redness, flaking, contact dermatitis — vehicle-dependent, often improved by switching to a less aggressive carrier.
• Headache, fatigue, low-libido days, mood flatness — reported by a minority, usually associated with higher-than-recommended dose or large application area; resolves on dose reduction or discontinuation.
• Slight breast-tissue tenderness — rare, usually self-limited.

• Tolerance buildup: No clear evidence of tolerance to AR antagonism with chronic use. Some long-term users report needing to maintain or slightly increase concentration; others report stable response over many years. Not well-characterized.
• Recommended cycle: None. Daily continuous is the operating model for AGA, which is itself a chronic condition.
• Reset protocol if needed: N/A — discontinuation simply lets the AR signal return and miniaturization resume.

Synergistic with

• Minoxidil (topical, 5%): Standard hair-loss community pairing. Different mechanisms (AR blockade vs. anagen extension / vasodilation), no PK interaction, often combined in same daily application. A-tier rationale by mechanism + heavy anecdotal support.
• Finasteride or dutasteride (oral): Mechanistically complementary (lower DHT + block AR locally) but the typical RU58841 user is avoiding the systemic 5α-reductase inhibitors — most do not stack. For users who tolerate finasteride well, adding RU58841 may produce modest additional benefit at marginal cost.
• Topical anti-inflammatory adjuncts (azelaic acid, ketoconazole shampoo) — for the inflammatory component of AGA. No interaction; possibly modestly synergistic.

Avoid stacking with

• Topical testosterone or any topical androgen application near the scalp — defeats the purpose by saturating local AR.
• Other topical AR antagonists (clascoterone / Winlevi, fluridil) without specific reason — receptor-saturation overlap with no additional benefit, more irritation risk.
• DMSO penetration-enhanced vehicles (community-level concern, not a true "drug interaction") — substantially increases systemic absorption and irritation.

Neutral / safe co-administration

• All of Dylan's V4 stack — no interaction with citicoline, NAC, magnesium, fish oil, theanine, rhodiola, curcumin, creatine, beta-alanine, vitamin D3, vitamin C, glycine, phosphatidylserine.
• Caffeine, modafinil, bromantane, Russian peptides — no interaction.

• CYP enzymes: Limited data. The closely related anilide-class anti-androgens (flutamide, bicalutamide) are CYP3A4 substrates and weak CYP3A4 inhibitors. Topical RU58841 at design-intent absorption levels should produce sub-therapeutic systemic concentrations and minimal CYP impact, but heavy use or compromised barrier could matter.
• No clinically significant documented interactions at standard topical use, in part because RU58841 has never been part of a regulatory drug-interaction studies program.
• Theoretical concerns — concomitant systemic AR antagonists (bicalutamide, abiraterone, enzalutamide), strong CYP3A4 inhibitors (azoles, macrolides) if substantial absorption.

• AR gene CAG repeat polymorphism: Shorter CAG repeats → more sensitive AR → more aggressive AGA pattern. Theoretically may also modulate response to RU58841 (more receptor blockade required), but unstudied.
• 5α-reductase type II (SRD5A2) variants: Affect DHT production but not directly RU58841 mechanism.
• CYP3A4 / CYP2D6: Could modulate metabolism of any RU58841 that escapes systemic deactivation. Not clinically applied.
• Practical note: No genetic test informs RU58841 dosing today. Dylan's 23andMe (~June 2026) will include AR-related calls but they are informational, not actionable for this molecule.

Reality check on research-chem sourcing: RU58841 has been sold for ~15 years on the gray market with periodic vendor disappearances, customs seizures (especially into the EU/UK), and quality variance. The most-trusted vendors at any given time turn over. The buyer is responsible for verifying purity (HPLC COA), confirming the molecule is RU58841 and not a near-analog like RU22930, and choosing or compounding a vehicle. This is meaningfully more friction than ordering finasteride from a telehealth provider. It is also legally murky in some jurisdictions (RU58841 is not scheduled, but importing unapproved drugs varies by country).

Dylan's sourcing comfort is research-chem-friendly with COA verification, so this is solvable when needed. The harder question is timing — there is no value in solving the sourcing puzzle before the indication exists.

• Baseline (before starting): Standardized photo series (Hamilton-Norwood standardized angles), scalp dermoscopy if available, total testosterone, free testosterone, LH, FSH, SHBG, estradiol (sensitive assay), prolactin, ALT/AST, lipid panel. For Dylan: irrelevant until an indication appears, but the June 2026 baseline panel covers most of these regardless.

• During use:

  • Photo series at month 3, 6, 12, then annually.
  • Hormone panel (T, LH, FSH, E2, prolactin) at month 6 and annually if any systemic-feeling symptoms.
  • LFTs at month 6 if heavy use (>1 mL/day, occluded, or DMSO vehicle).
  • Symptom diary (libido, mood, energy, breast tenderness, scalp condition).

• Post-cycle (if cycled): N/A for chronic use.